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Purpose: To evaluate the prevalence of thrombophilic disorders 
in polycystic ovarian syndrome (PCOS) women with history of 
recurrent pregnancy loss (RPL). Materials and methods: This 
study was carried out in 184 women with history of RPL, of 
which 92 of them were diagnosed with PCOS and 92 patients 
were without known PCOS. The prevalence of thrombophilic 
disorders was compared between the two mentioned groups. 
Results: According to the findings, 70.7% of PCOS women with 
history of RPL had thrombophilic disorders. The prevalence 
of protein C deficiency was significantly higher in PCOS group 
compared to the non-PCOS group (21.7% vs. 10.9%, p = 0.04). 
There was a trend toward higher prevalence of protein S defi-
ciency in PCOS group compared to the control group, but the 
difference did not reach statistical significance (23.9% vs. 13%, 
p = 0.05). The prevalence of other thrombophilic disorders such 
as antithrombin III deficiency, homocysteine elevation, antiphos-
pholipid antibody and Factor V Leiden was comparable between 
groups. Conclusion: The prevalence of thrombophilic disorders 
was more common in PCOS women than the normal group. The 
protein C deficiency is associated with PCOS in women with 
history of RPL. There was a trend toward higher prevalence of 
protein S deficiency in PCOS women, which needs further study.
Keywords: Polycystic ovarian syndrome, recurrent pregnancy 
loss, thrombophilia, thrombophilic factor
Introduction
Polycystic ovarian syndrome (PCOS) is the most common hetero-
geneous endocrine disorder [1] which affects about 5%–10% of 
reproductive-aged women [2,3]. This syndrome is considered as 
the most common cause of anovulatory infertility and hirsutism 
[1] and characterized by oligomenorrhea, amenorrhea, anovu-
lation, abnormal gonadotropins, androgen excess, polycystic 
ovarian morphology, type 2 diabetes mellitus, obesity, acne, skin 
hyperpigmentation and hyperinsulinemia [4–7].
PCOS is also associated with pregnancy complications such as 
recurrent miscarriage. The prevalence of PCOS in women with 
history of recurrent pregnancy loss (RPL) has been reported in 
a wide range of 10%–82% in different studies [8–10]. But the 
possible mechanisms by which PCOS could cause recurrent 
miscarriage remain controversial.
Recent studies suggest an association between hereditary 
thrombophilia and pregnancy loss. Activated protein C (APC) 
resistance due to Factor V Lieden mutations is associated 
with sporadic and RPL [11,12]. Furthermore, MTHFR C677T 
homozygosity, protein S, protein C and antithrombin III (ATIII) 
deficiencies and antiphospholipid syndrome could be responsible 
for most of the RPL [13,14]. Uteroplacental vascular insufficiency 
due to thrombotic effects of thrombophilia predispose pregnant 
women to pregnancy failure and fetal loss [15].
On the other hand, several studies have been made to evaluate 
the association of thrombophilia, PCOS and RPL [12,16–20]. 
However, there are still no sufficient evidences whether thrombo-
philic disorders can be considered as a causal factor of recurrent 
miscarriage in PCOS women.
If women with PCOS are really predisposed for thrombophilic 
disorders, they will probably have poor prognosis in pregnancy 
and treatment strategies should be considered before any deci-
sion for pregnancy. In this study, we aimed to evaluate the preva-
lence of thrombophilic disorders in PCOS women with history 
of RPL.
Methods
This case control study was carried out in 184 women aged 
20–40 years during 2009–2010 in recurrent miscarriage clinic of 
Roointan-Arash Hospital, Tehran, Iran. The study population was 
women with history of RPL who were referred for diagnosis and 
treatment. Ninety-two patients were diagnosed with PCOS and 
92 were without known PCOS.
This study was approved by Tehran University of Medical 
Science’s Ethics Committee and informed consent was obtained 
from all subjects. Primary evaluation was performed through 
physical examination, menstrual and obstetrical history, medical 
and surgical history, family history and measurement of blood 
pressure and body mass index.
The inclusion criteria included women with history of RPL 
who were free of other etiologies for RPL such as uterine struc-
tural abnormalities (assessed by sonogram, hysterosalpingogram, 
hysteroscopy or laparoscopy), myoma, Asherman’s syndrome and 
cervical incompetence. Any women with inflammatory, hema-
tological and thromboembolic diseases, hypothyroidism, malig-
nancy, Cushing’s syndrome and liver diseases were excluded from 
the study. Current pregnancy, delivery or miscarriage occurring 
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within the preceding 3 months, recent surgery, recent sex steroid 
therapy and recent use of anticoagulation drugs (warfarin, heparin 
and aspirin) and diabetic drugs (metformin) were other exclusion 
criteria.
Diagnosis of PCOS was established based on Rotterdam 
criteria [21] and presence of at least two criteria defined as PCOS. 
RPL was defined by three or more consecutive pregnancy losses 
below 20 weeks of gestation.
Laboratory assays
Venipuncture was performed on all fasting women on day 3 of 
menstrual cycle in order to assess thrombophilic factors. Venous 
blood was collected on both 3.2% trisodium citrate anticoagulant 
and clot activator by means of Ayset vacuum blood collection 
tubes (Ayset Plastik Tekstil ve Elektronik, Adana, Turkey). The 
tubes were immediately centrifuged at 3500 rpm for 15 min at 
room temperature to obtain relatively platelet-free plasma/serum. 
Plasma/serum was then frozen and stored in small aliquots at 
− 70 °C until assayed.
Protein S, protein C and Factor V Leiden were assessed 
using the clotting assay kits (HEMOCLOT; HYPHEN Biomed, 
Neuville-Sur-Oise, France). AT activity was measured using 
a chromogenic assay (BIOPHEN AT 2.5). Homocysteine 
and antiphospholipid antibodies were measured by means 
of the enzyme immunoassay kits (Axis Homocysteine EIA; 
Axis-Shield Diagnostics Ltd., Dundee, UK, and AESKULISA 
Phospholipid-Screen-GM; AESKU.Diagnostics, Wendelsheim, 
Germany).
Statistical analysis
Statistical analysis was performed by SPSS software version 13 
(SPSS Inc., Chicago, IL, USA). In order to compare the mean 
age and mean body mass index of the two groups, an indepen-
dent T analysis was used. A chi square test was used to compare 
hormonal abnormalities and abnormal glucose tolerance test 
(GTT) between groups. We also used a chi square test or Fisher’s 
exact test to compare all thrombophilic disorders between two 
groups. A p value <0.05 was considered statistically significant.
Results
In this case control study, the prevalence of thrombophilic disor-
ders in 92 PCOS and 92 non-PCOS women with history of RPL 
was compared. According to the findings, there were no significant 
differences in the mean age (p = 0.92) and body mass index (p = 0.78) 
of women between groups (Table I). Among women with PCOS, 
49 patients (53.3%) were found to have testosterone levels higher 
than normal range versus 22 patients (23.9%) in non-PCOS group 
(p < 0.001), 38 patients (41.3%) had luteinizing hormone/follicle-
stimulating hormone ratio > 2 which was significantly higher than 
24 women (26.1%) in control group (p = 0.029) and 20 women 
(21.7%) in each group had abnormal levels of prolactin (p = 1.00). 
Forty patients (43.5%) in the PCOS group and 10 (10.9%) in the 
control group had abnormal GTT 1 h with 75 g glucose (p < 0.001). 
Overt diabetes of 4.3% was observed in PCOS women, which was 
significantly higher than the control group (p = 0.043).
Nearly 70.7% of PCOS women with history of RPL had throm-
bophilic disorders, which were significantly different with 47.8% 
in non-PCOS women group (p = 0.002). About 21.7% of women 
with PCOS had protein C deficiency versus 10.9% in the control 
group (p = 0.04) (Table II).
Although protein S deficiency was not significantly different 
between groups, there was a trend toward higher prevalence of 
protein S deficiency in PCOS women compared to the control 
group (23.9% vs. 13%, p = 0.05) (Table II).
The prevalence of other thrombophilic disorders such as 
ATIII deficiency, Factor V Leiden, abnormal homocysteine and 
antiphospholipid antibody was comparable between groups 
(p = 1.00, 1.00, 0.78 and 1.00, respectively) (Table II).
Discussion
Thrombophilias are a group of acquired or genetic blood coagula-
tion disorders which predispose patients to vascular thrombosis 
and pregnancy complications, including early pregnancy loss 
[12,22,23].
Deficiencies of natural anticoagulants protein C, protein S 
and AT and also hyperhomocysteinemia, Factor V Leiden and 
APC resistance are thrombophilic defects that increase the risk 
of thrombosis [24].
According to the findings, 70.7% of PCOS women with 
history of RPL had thrombophilic disorders, which were 
significantly different with 47.8% in non-PCOS women group. 
The prevalence of protein C deficiency in the PCOS group 
was 21.7%, which was significantly different with 10.9% in the 
non-PCOS women group. There was a trend toward higher 
prevalence of protein S deficiency in the PCOS group compared 
to the control group, even though it didn’t achieve statistical 
significance. Therefore, it seems that in further study with 
greater population, significant difference of protein S might be 
observed between groups.
AT is the most important inhibitor of blood coagulation 
[25]. Inherited ATIII deficiency is associated with a long-term 
complication of venous thromboembolism [25]. High incidence 
of poor pregnancy outcome among AT-deficient women was also 
reported [26]. The prevalence of inherited AT deficiencies in the 
general population is very uncommon (between 1 in 600) [27]. In 
this study, ATIII deficiency was found in four women (4.3%) of 
each group, which was more common compared to the general 
population.
In contrast to our findings, in the study by Tsanadis et al. [16], 
all patients in PCOS and non-PCOS groups showed normal 
median proportions of APC, protein S and ATIII. They reported 
Table I. Characteristics of women in two studied groups.
 PCOS (n = 92)
Non-PCOS 
(n = 92) p value
Age (years) 29.16 ± 2.32 29.13 ± 2.33 NS
Body mass index (kg/m2) 23.87 ± 4.44 24.06 ± 4.5 NS
Data are expressed as mean ± SD.
PCOS, polycystic ovarian syndrome; NS, not statistically significant.





(n = 92) p value
Protein S deficiency (%) 22 (23.9) 12 (13) NS 
(0.05)
Protein C deficiency (%) 20 (21.7) 10 (10.9) 0.04
Antithrombin III deficiency (%) 4 (4.3) 4 (4.3) NS
Factor V Leiden (%) 3 (3.3) 3 (3.3) NS
Homocysteine elevation (%) 8 (8.7) 7 (7.6) NS
Antiphospholipid antibody (%) 8 (8.7) 8 (8.7) NS
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that recurrent fetal loss in PCOS women might be due to other 
mechanisms rather than thrombophilic disorders. Tsanadis et al. 
conducted a preliminary study with 30 PCOS women and 45 
non-PCOS group from Greece, whereas the present study was 
based on a greater sample of 184 women (92 PCOS and 92 non-
PCOS) who were all Iranian population with history of recurrent 
miscarriage.
Factor V Leiden is a genetic state that results in APC resistance 
and is considered as an important risk factor for systemic venous 
thrombosis. In a previous study, women with PCOS had the same 
prevalence of APC resistance compared to the general popula-
tion [19]. Similarly, the low insignificant prevalence of Factor V 
Leiden in this study (3.3% in each group) demonstrated that this 
factor probably does not play any role in thrombotic disorders 
and fetal loss in PCOS patients.
It is now widely accepted that hyperhomocysteinemia could be 
a thrombotic risk factor in PCOS women. In a study by Cerqueira 
et al. [28], higher serum level of homocysteine was reported in 
PCOS patients compared to the control group. In the current 
study, the prevalence of abnormal level of homocysteine in both 
groups was within the normal range expected for general popula-
tion and no significant difference was found.
However with respect to the current study, serum homo-
cysteine level would not be a valuable marker for prediction of 
pregnancy thrombotic events due to PCOS such as fetal loss. On 
the other hand, in most cases, blood homocysteine concentration 
is probably affected by several factors including vitamin status, 
diet, age and genotype of the patients [29].
We recently evaluated thrombophilic factors such as protein 
S, protein C, ATIII, APC resistance and homocysteine levels 
in PCOS and non-PCOS patients and no association between 
thrombophilia and PCOS in infertile women was observed [17].
Antiphospholipid antibody syndrome is regarded as the most 
frequently acquired risk factor for thrombophilia which is respon-
sible for many pregnancy losses [30]. Most of the cases in the 
current study had normal levels of this factor. These results indi-
cate that antiphospholipid antibody does not play a role in PCOS 
and RPL. However, no previous study regarding antiphospholipid 
antibody as a thrombophilic factor in PCOS women is available in 
the literature and further research of this kind would be required.
Ultimately, the prevalence of thrombophilic disorders was 
more common in PCOS women than the normal group. The 
protein C deficiency is associated with PCOS in women with 
history of RPL. There was a trend toward higher prevalence of 
protein S deficiency in PCOS women but the difference did not 
reach statistical significance. Thus, the statistically significant 
difference might be achieved with further study with a greater 
population.
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